Nurtec ODT is the brand name for rimegepant, an oral dissolving tablet prescribed to treat and prevent migraine. Employees who take it sometimes ask whether it will trigger a positive result on a pre employment or workplace drug screen. The short answer is no. Rimegepant is not a controlled substance, it is not included in any standard or expanded workplace drug test panel, and there is no published evidence that it cross reacts with the immunoassay screens used in urine, oral fluid, or hair testing.
This post explains how rimegepant works, why it falls outside the drug classes that workplace panels are built to detect, which migraine medications employers and medical review officers actually need to think about, and what an employee on Nurtec ODT should do if a question comes up during screening.
What Nurtec ODT actually is
Rimegepant is a calcitonin gene related peptide (CGRP) receptor antagonist. According to the current prescribing information on file with the agency, it works by blocking the CGRP receptor, a mechanism involved in the transmission of migraine pain, rather than acting on opioid, cannabinoid, benzodiazepine, or amphetamine receptors. That mechanism is also why it behaves nothing like the drug classes that employment drug panels are designed around. You can review the full FDA labeled prescribing information, including the mechanism of action and clinical pharmacology sections, in the original official label for Nurtec ODT.
The current, continuously updated version of the label is maintained in the National Library of Medicine's DailyMed system, which hosts the official FDA labeling that manufacturers are required to keep current. The DailyMed label for Nurtec ODT (rimegepant sulfate) lists the drug's indications, dosage, and full prescribing details, and nowhere does it describe rimegepant as a scheduled or controlled substance under the Controlled Substances Act.
Why standard and expanded panels do not detect it
Workplace urine and oral fluid screens use immunoassay test strips or cups built to react to specific drug classes: amphetamines, cocaine metabolites, opiates, phencyclidine, and THC metabolites on a basic federal panel, with benzodiazepines, barbiturates, methadone, propoxyphene, or expanded opioids added on broader panels. The federal workplace testing program that sets the baseline for these panels is defined in the Department of Transportation's drug and alcohol testing regulation. The specific analytes required on a federally regulated DOT test are listed in 49 CFR 40.87, which sets the initial and confirmatory drug tests and their cutoff concentrations, and the broader structure of the testing program, including who must be tested and how specimens are handled, is set out in 49 CFR Part 40.
Rimegepant does not belong to any of the drug classes named in that regulation. It is not an opioid, not an amphetamine, not a benzodiazepine, not a barbiturate, and not a cannabinoid. Because immunoassay screening strips are built around antibodies that bind to the chemical structure of those specific classes, a drug with an unrelated structure and receptor target, like a CGRP antagonist, has no mechanism to trigger a positive screen. There is no published clinical or laboratory literature documenting cross reactivity between rimegepant and standard immunoassay panels, and the manufacturer's FDA labeling does not list any interference with drug of abuse testing. When no cross reactivity data exists for a medication, the accurate statement is that the evidence is limited or absent, not that cross reactivity has been ruled out in every possible assay formulation used by every manufacturer.
The migraine medications that actually matter to a testing program
Nurtec ODT is one of several medications prescribed for migraine, and not all of them are irrelevant to a workplace panel. Employers and medical review officers (MROs) should be aware of the difference.
| Medication class | Example | Relevant to standard drug panels | Why |
|---|---|---|---|
| CGRP receptor antagonists (gepants) | Rimegepant (Nurtec ODT), ubrogepant | No | Not a controlled substance, not structurally related to any screened drug class |
| Triptans | Sumatriptan, rizatriptan | No | Serotonin receptor agonists, not controlled substances, no documented cross reactivity |
| Barbiturate combination analgesics | Butalbital compounds (Fioricet) | Yes | Butalbital is a barbiturate and can be detected on a barbiturate panel |
| Opioid analgesics sometimes prescribed for migraine | Hydrocodone, codeine combinations | Yes | Opioids are screened on standard and expanded opiate panels and require prescription verification |
| CGRP monoclonal antibodies (preventive injectables) | Erenumab, fremanezumab | No | Biologic antibody, not a small molecule drug of abuse |
The barbiturate and opioid rows are where real MRO review happens. A patient who has been prescribed a butalbital combination product or an opioid for migraine, cluster headache, or another condition should expect that an opiate or barbiturate positive will be flagged for review, and that documentation of a valid prescription from a licensed practitioner is what resolves it. A patient on Nurtec ODT alone has nothing in that drug's chemistry for a panel to detect in the first place.
What to do if the subject comes up during screening
Because rimegepant is not screened for, there is normally nothing for an employee to disclose about it in connection with a drug test. If a laboratory ever reports an unexpected result during migraine treatment, the standard path is the same one used for any other prescription medication question: the collection site or laboratory forwards nonnegative results to a medical review officer, a physician trained and qualified under the federal program, who contacts the employee to review current prescriptions before any result is reported to the employer as positive. The Substance Abuse and Mental Health Services Administration, which sets and maintains the federal workplace drug testing guidelines that many non federal employers also model their programs on, describes the role of certified laboratories and MRO review in federal workplace testing on its workplace drug testing program page. Employees should keep a copy of their prescription or a note from the prescribing clinician available in case any medication question arises during the review process, rather than relying on verbal explanation alone.
None of this is medical advice. Questions about whether to start, stop, or continue a migraine medication, or how it might interact with another prescription, belong with the prescribing clinician, not with an employer's drug testing policy.
What this means for employer drug testing programs
Employers building or maintaining a drug free workplace program do not need to add anything to their panel configuration because an employee is taking Nurtec ODT or a similar gepant medication. The standard 5 panel, 7 panel, 10 panel, or expanded opioid configurations already in use are unaffected, because none of them target the CGRP pathway. Programs that want to review their current panel configuration against current federal analyte lists can reference 49 CFR 40.85, which lists the drugs and drug metabolites for which a laboratory must test under the DOT program. Facilities that supply their own collection cups, oral fluid devices, or confirmation testing can review current panel configurations and cup formats through the drug test cup collection or order in bulk through the wholesale portal.
For background on how opiate containing migraine treatments are handled on a standard panel, see Does Hydrocodone Show Up on a Drug Test?, and for the barbiturate containing combination product sometimes prescribed for migraine and tension headache, see Does Fioricet Show Up on a Drug Test?.
Frequently asked questions
Does Nurtec ODT show up on a standard 5 panel or 10 panel drug test?
No. Standard and expanded workplace panels are built to detect amphetamines, cocaine metabolites, opiates, PCP, THC, and in expanded versions benzodiazepines, barbiturates, and additional opioids. Rimegepant, the active ingredient in Nurtec ODT, is not a controlled substance and is not part of any of those drug classes, so there is no screening target for it to trigger.
Is rimegepant a controlled substance?
No. Rimegepant is not scheduled under the Controlled Substances Act. Its FDA labeling, available through DailyMed, does not list any federal scheduling, and it is prescribed and dispensed as a non controlled prescription medication.
Could Nurtec ODT cause a false positive on an opiate or amphetamine screen?
There is no published evidence of cross reactivity between rimegepant and the immunoassay antibodies used in opiate, amphetamine, benzodiazepine, or any other standard drug class screen. The evidence available is limited to the absence of any documented interference in the drug's FDA labeling and the lack of published cross reactivity studies, which supports a conclusion that cross reactivity is not expected, not that every assay on the market has been individually tested.
What migraine medications should an employer or MRO actually pay attention to?
Butalbital containing combination products, such as Fioricet, contain a barbiturate and can be detected on a barbiturate panel. Opioid medications sometimes prescribed for severe migraine or cluster headache, such as hydrocodone or codeine combinations, are detected on standard or expanded opiate panels. Triptans and CGRP targeted therapies, including rimegepant, are not detected on any standard panel.
What should an employee on Nurtec ODT do before a drug test?
Because rimegepant is not a screened substance, there is typically nothing to disclose about it specifically. Employees taking any prescription medication should keep documentation available in case a medical review officer needs to review current prescriptions as part of resolving a nonnegative result unrelated to the migraine medication.
Does lab confirmation testing change this answer?
No. GC/MS or LC/MS confirmation testing is run to confirm or rule out a specific drug class after an initial immunoassay screen flags a presumptive positive. Because rimegepant does not trigger the initial immunoassay screen in the first place, there is no pathway by which it would reach confirmation testing for a drug of abuse panel.
This article is general information for employers and employees about drug testing panels and prescription medications. It is not medical or legal advice. Questions about a specific medication or health condition should go to a licensed clinician, and questions about a specific testing policy should go to qualified legal counsel or the employer's medical review officer.
